Clinical Design and Objectives

AN9025 is an orally administered RAS inhibitor being evaluated in a Phase 1 trial for safety and tolerability. The primary objectives are to identify a safe dose in patients with RAS‑mutated solid tumors and to explore early signals of antitumor activity. The study administers the drug once daily or once weekly, and treatment is discontinued upon disease progression or the occurrence of serious adverse events.

Patient Population and Treatment Landscape

Enrolled patients have progressive or metastatic solid tumors harboring a RAS mutation, often with limited standard therapeutic options. Currently, agents that directly target RAS mutations are scarce, and most standard care relies on chemotherapy or immunotherapy. Consequently, AN9025 may offer a differentiated mechanism of action relative to existing treatments.

Trial Conduct and Timeline

The trial commenced on January 28, 2026 and is actively enrolling. Participants attend the clinic 3–4 times during the first 21 days for blood draws and, when required, tumor tissue sampling. Subsequent assessments occur every 21 days, with additional visits at 14 and 30 days after treatment discontinuation. Long‑term safety monitoring includes status checks every three months.

Market and Clinical Significance

Although still in Phase 1, direct inhibitors of RAS mutations have not yet reached the market, generating considerable anticipation. A favorable safety profile would lay a critical foundation for confirming anticancer efficacy in subsequent Phase 2 and 3 studies. This could create a novel therapeutic option for the RAS‑mutated patient cohort and present a new pipeline opportunity for biopharma investors.